1 Recommendations

1 Recommendations

1.1 The evidence on transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia raises no major safety concerns. The evidence on efficacy is limited in quantity. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

1.2 Clinicians wishing to do transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia should:

  • Inform the clinical governance leads in their NHS trusts.

  • Ensure that patients understand the uncertainty about the procedure's efficacy and provide them with clear written information to support shared decision-making. In addition, the use of NICE's information for the public is recommended.

  • Audit and review clinical outcomes of all patients having transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE has identified relevant audit criteria and has developed an audit tool (which is for use at local discretion).

1.3 The procedure should only be done by clinicians who have been trained in the technique.

1.4 NICE encourages further research into transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia and may update the guidance on publication of further evidence. Further research should report long-term follow‑up and include reintervention rates.

  • National Institute for Health and Care Excellence (NICE)